Загрузка...
Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials
The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B, given during antibiotic treatment for Clostridioides difficile infection (CDI) significantly reduced C. difficile recurrence (rCDI) in adults at high risk for rCDI. Efficacy o...
Сохранить в:
| Опубликовано в: : | Eur J Clin Microbiol Infect Dis |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7497347/ https://ncbi.nlm.nih.gov/pubmed/32504314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10096-020-03935-3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|